ReviewInfection and drug resistance2026
The Auranofin-Colistin Combination Efficiency Against the Gram-Negative Strains: A Review.
Review in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug-resistant bacteria that possess resistance genes against last-resort antibiotics, such as colistin, are notably prevalent in hospital environments. Therapeutic options for addressing these infections are limited, prompting researchers to explore alternative strategies. One promising approach is drug repurposing, which involves testing combinations of antibiotics with other medications to discover potential synergistic effects against multidrug-resistant (MDR) strains. Auranofin, an antirheumatic drug known for its anti-inflammatory and antineoplastic properties, has recently been investigated in combination with colistin as a potential therapeutic strategy for treating infections caused by multidrug-resistant bacteria. A review of 10 articles retrieved from five public scientific databases indicates that all authors reported synergistic activity of the auranofin-colistin combination against multidrug-resistant (MDR) species, with effectiveness demonstrated in both in vitro and in vivo experiments. However, the minimal inhibitory concentrations (MICs) of this combination vary, and the precise mechanism of action remains unclear. Recent studies examining the crystal structure of metallo-beta-lactamase type 2 (NDM-1) and a probable phosphatidylethanolamine transferase, MCR-1 (which confers mobilized colistin resistance), suggest that activation with glutathione or N-acetylcysteine is necessary for efficacy. Additionally, there is strong evidence indicating that auranofin acts as a dual inhibitor of both MCR and metallo-beta-lactamase (MBL) by displacing the Zn(II) cofactor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.